All In MedTech

FDA Clearance Tracker · P150048-S092

TRIFORMIS RESILIA Tricuspid Valve

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 27, 2025

Approved

Time to decision

180 days

Received Apr 30, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150048-S092
Device name
TRIFORMIS RESILIA Tricuspid Valve
Applicant location
Irvine, CA
Received
Apr 30, 2025
Decided
Oct 27, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150048

Device type

Device class
Class III

Every decision under product code LWR

FDA's approval statement

As written in FDA's record.

Approval for the MITRIS RESILIA Mitral Valve for expanding the indications to include the tricuspid position. The device, as modified, will be marketed under the trade name “TRIFORMIS RESILIA Tricuspid Valve” and is indicated for the replacement of native or prosthetic tricuspid heart valves.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.